Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant

McMaster University

$100,000.00

Determining the fate of tumour cells killed by an oncolytic virus.

EF 2008-09

Résumé
We are proposing to investigate a largely ignored aspect of using viruses to kill cancer cells. In this proposal we will examine the removal of tumour cell corpses by the immune system following oncolytic viral therapy and how this leads to immunity against the cancer. The role and contributions of various "eating" cells in the immune system to the removal and processing of killed tumour cells will be assessed as we develop means of manipulating this to enhance anti-tumour immunity following oncolytic viral therapy. We will also test engineered viruses designed to enhance the consumption of dead and dying cancer cells by these "eating" cells that will then display tumour-specific proteins to the immune system. The combination of oncolytic viral therapies with immunotherapy could lead to significant tumour destruction by the virus followed by an immune response against the cancer that could eliminate it. A patient that is rendered immune to their cancer would be much less likely to relapse as the immune system will act to prevent this.
Programme
Operating Grant
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
183797
Name
Lichty Brian D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Biology & Therapeutics
Projecttitle
Determining the fate of tumour cells killed by an oncolytic virus.
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Oncolytic Viruses; Tumour Immunology; Viral Vectors
Abstract
We are proposing to investigate a largely ignored aspect of using viruses to kill cancer cells. In this proposal we will examine the removal of tumour cell corpses by the immune system following oncolytic viral therapy and how this leads to immunity against the cancer. The role and contributions of various "eating" cells in the immune system to the removal and processing of killed tumour cells will be assessed as we develop means of manipulating this to enhance anti-tumour immunity following oncolytic viral therapy. We will also test engineered viruses designed to enhance the consumption of dead and dying cancer cells by these "eating" cells that will then display tumour-specific proteins to the immune system. The combination of oncolytic viral therapies with immunotherapy could lead to significant tumour destruction by the virus followed by an immune response against the cancer that could eliminate it. A patient that is rendered immune to their cancer would be much less likely to relapse as the immune system will act to prevent this.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lichty, Brian D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~